期刊文献+

异丙酚前药HX0891和HX0892在大鼠体内的初步药效学评价 被引量:4

Initial pharmacodynamics evaluation of Propofol prodrug HX0891 and HX0892 in the rats
原文传递
导出
摘要 目的通过体内和体外实验对异丙酚前药HX0891和HX0892进行初步药效学评价。方法稳定性实验证明体内实验中给予的前药没有分解;体外血浆释放实验证明两个前药是否能分解产生异丙酚;体内实验用上下法测定两个前药的半数有效量(ED50),并和异丙酚和磷丙泊酚钠进行药效学对比。结果 HX0892的体外血浆分解量大于HX0891,分解速度也快于HX0891;体内实验中,HX0891、HX0892的ED50分别为121.76、98.40 mg.kg-1,在等效剂量下,二者的维持时间都比异丙酚和磷丙泊酚钠显著加长。结论 HX0891和HX0892的起效时间慢,但维持时间显著延长,可能适用于临床镇静;二者的安全性与有效性需进一步研究。 OBJECTIVE To evaluation initial pharmacodynamic of HX0891 and HX0892 was conducted in rats by in vitro and in vivo studies.METHODS Stability study was conducted to guarantee that no propofol was released before injection.HX0891 and HX0892 were added into the plasma of rat respectively to observe the release of propofol.ED50 of HX0891 and HX0892 in rats was determined by up-and-down method.Pharmacodynamic comparsion with propofol and fospropofol was also conducted.RESULTS Conversion rate and degree of HX0892 was greater than that of HX0891.ED50 of HX0891 and HX0892 were 121.76 mg·kg-1 and 98.40 mg·kg-1,respectively.The duration time of these two compounds in blood was significantly longer than that of propofol and fospropofol.CONCLUSION The onset time of HX0891 and HX0892 was delayed with a longer duration time.Maybe they can be used for sedation.More studies were needed to investigate the efficacy and safety of these two compounds.
出处 《华西药学杂志》 CAS CSCD 北大核心 2012年第1期45-47,共3页 West China Journal of Pharmaceutical Sciences
关键词 异丙酚 水溶性 前药 药效学 Propofol Water soluble Prodrug Pharmacodynamic
  • 相关文献

参考文献8

  • 1Baker MT, Nagnib M. Propofol : the challenges of formulation [ J ].Anesthesiology,2005,103 (4) : 860 - 876.
  • 2Garnock - Jones KP, Scott LJ. Fospropofol [ J ]. Drugs, 2010,70(4) :469 -477.
  • 3Altomare C, Trapani G, Latrofa A, et al. Highly water " solublederivatives of the anesthetic agent propofol: in vitro and in vivoevaluation of cyclic amino acid esters [ J ]. Eur J Pharm Sci,J 2003,20(1) :17 -26.
  • 4Paul M, Fisher DM. Are estimates of MAC reliable [ J ].Anesthe-siology ,2001,95 ( 6 ) : 1362 - 1370.
  • 5Kilpatrick GJ,Mclntyre MS,Cox RF,et al. CNS 7056 :a novel ul-tra - short - acting Benzodiazepine [ J ]. Anesthesiology,2007,107(1) :60 -66.
  • 6Morey TE,Modell JH,Shekhawat D,et al. Preparation and anes-thetic properties of propofol microemulsions in rats[ J]. Anesthe-siology, 2006,104 ( 6 ) : 1184 - 1190.
  • 7Fast JP, Perkins MG, Pearce RA, et al. Fluoropolymer - basedemulsions for the intravenous delivery of sevoflurane [ J ]. Anes-thesiology,2008,109 (4) :651 - 656.
  • 8Kumpulainen H,Jarvinen T, Mannila A,et al. Synthesis, in vitroand in vivo characterization of novel ethyl dioxy phosphate prodrugof propofol[ J]. Eur J Pharm Sei,2008,34(2 -3) :110 - 117.

同被引文献60

  • 1易静,郝晓柯,苏明权.肿瘤的酶-前药疗法[J].国外医学(肿瘤学分册),2005,32(6):413-416. 被引量:1
  • 2何亮.前药的研究进展[J].世界临床药物,2006,27(1):55-58. 被引量:8
  • 3李铭东,吉民.肿瘤活化前药的研究与应用进展[J].药品评价,2006,3(3):206-213. 被引量:1
  • 4Stella VJ, Himmelstein KJ. Prodrugs and site-spe- cific drug delivery[J].J Med Chem, 1980, 23(12) : 1275-1282.
  • 5Testa B. Prodrugs: bridging pharmacodynamic/ pharmacokinetic gaps [J]. Curr Opin Chem Biol, 2009, 13(3): 338-344.
  • 6Ettmayer P, Amidon GL, Clement B, et al. Les- sons learned from marketed and investigational pro- drugs [J]. J Med Chem, 2004, 47(10): 2393- 2404.
  • 7Beaumont K, Webster R, Gardner I, et al. Design of ester prodrugs to enhance oral absorption ofpoorly permeable compounds: challenges to the dis- covery scientists[J]. Curr Drug Metab, 2003, 4 (6) : 461-485.
  • 8Wu KM. A new classification of prodrugs: regula- tory perspectives[J]. Pharmaceuticals, 2009, 2 (3):77-81.
  • 9Rautio J, Kumpulainen H, Heimbach T, et al. Prodrugs: design and clinical applications[J].Nat Rev Drug Discov, 2008, 7(3) : 255-270.
  • 10Testa B. Prodrug research: futile or fertile[J]. Bio- chem Pharmacol, 2004, 68(11): 2097-2106.

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部